GlassScriptPhysician profile
Alan K Cole
NPI 1629264544
$6,230.25
in general payments reported to CMS, 2019-2025
32 companies · $702 in 2025
The $702 reported for 2025 was more than what a typical Pain Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $405).
See the full distribution for Pain Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $1,104 · 2021: $1,187 · 2022: $1,039 · 2023: $600 · 2024: $672 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,973.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,041.93 | 2021-2025 | Ubrelvy, Qulipta |
| Amgen INC. | $759.92 | 2019-2022 | |
| Lilly USA, LLC | $737.17 | 2019-2024 | Emgality, Reyvow |
| Supernus Pharmaceuticals, INC. | $417.01 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $371.10 | 2022-2025 | Relistor |
| Lundbeck LLC | $360.44 | 2022-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $317.32 | 2019-2024 | Ajovy |
| Valinor Pharma, LLC | $271.17 | 2023-2025 | Movantik |
| Pfizer INC. | $259.20 | 2019-2025 | |
| Allergan, INC. | $229.27 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $213.32 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $207.32 | 2020-2021 | |
| Upsher-Smith Laboratories LLC | $161.38 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $112.77 | 2019-2022 | |
| Abbott Laboratories | $107.26 | 2019-2025 | Eterna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $98.75 | 2023-2024 | Tirosint, Licart, Licart |
| Redhill Biopharma INC. | $90.03 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $85.10 | 2019-2021 | |
| Forte Bio-Pharma LLC | $56.79 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Currax Pharmaceuticals LLC | $41.91 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $37.13 | 2019-2020 | |
| Amarin Pharma, INC. | $34.78 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $32.35 | 2019 | |
| Biodelivery Sciences International, INC. | $30.70 | 2019-2021 | |
| Shionogi INC | $30.38 | 2019 | |
| Siemens Medical Solutions USA, INC. | $23.19 | 2021 | |
| Boston Scientific Corporation | $19.88 | 2019 | |
| Axsome Therapeutics, INC. | $18.72 | 2025 | Symbravo |
| United Imaging Healthcare North America LLC | $18.15 | 2020 | |
| Assertio Therapeutics, INC. | $17.50 | 2019 | |
| Ge Healthcare | $14.75 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $13.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.